Innate Pharma (NASDAQ:IPHA – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Thursday, Marketbeat.com reports. They currently have a $1.00 target price on the stock. Leerink Partners‘s price target would suggest a potential upside of 15.82% from the company’s current price.
Other equities analysts have also issued research reports about the stock. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating on shares of Innate Pharma in a research report on Thursday, November 5th. HC Wainwright restated a “buy” rating on shares of Innate Pharma in a research report on Monday, September 21st. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Innate Pharma in a report on Tuesday, September 22nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.67.
Check Out Our Latest Analysis on Innate Pharma
Innate Pharma Stock Down 8.1%
Innate Pharma Company Profile
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.
See Also
- Five stocks we like better than Innate Pharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
